[go: up one dir, main page]

JOP20220169A1 - مثبطات ببتيدية لمستقبلة انترلوكين-23 واستخدامها في معالجة الأمراض الالتهابية - Google Patents

مثبطات ببتيدية لمستقبلة انترلوكين-23 واستخدامها في معالجة الأمراض الالتهابية

Info

Publication number
JOP20220169A1
JOP20220169A1 JOP/2022/0169A JOP20220169A JOP20220169A1 JO P20220169 A1 JOP20220169 A1 JO P20220169A1 JO P20220169 A JOP20220169 A JO P20220169A JO P20220169 A1 JOP20220169 A1 JO P20220169A1
Authority
JO
Jordan
Prior art keywords
interleukin
receptor
peptide inhibitors
inflammatory diseases
treat inflammatory
Prior art date
Application number
JOP/2022/0169A
Other languages
English (en)
Inventor
Raffaele Ingenito
Raymond Patch
Danila Branca
Ashok Bhandari
Gregory Thomas Bourne
Elisabetta Bianchi
Sandeep Somani
Chengzao Sun
Brian Troy Frederick
Roberto Costante
Original Assignee
Janssen Biotech Inc
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Protagonist Therapeutics Inc filed Critical Janssen Biotech Inc
Publication of JOP20220169A1 publication Critical patent/JOP20220169A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

يزود الاختراع الحالي مثبطات ببتيدية peptide inhibitors جديدة لمستقبلة إنترلوكين interleukin-23 وتراكيب ذات صلة وطرق لاستخدام هذه المثبطات الببتيدية في معالجة أو الوقاية من مجموعة متنوعة من الأمراض والاضطرابات، بما في ذلك أمراض الأمعاء الالتهابية inflammatory bowel diseases.
JOP/2022/0169A 2020-01-15 2021-01-14 مثبطات ببتيدية لمستقبلة انترلوكين-23 واستخدامها في معالجة الأمراض الالتهابية JOP20220169A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062961624P 2020-01-15 2020-01-15
PCT/US2021/013463 WO2021146441A1 (en) 2020-01-15 2021-01-14 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Publications (1)

Publication Number Publication Date
JOP20220169A1 true JOP20220169A1 (ar) 2023-01-30

Family

ID=76864704

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0169A JOP20220169A1 (ar) 2020-01-15 2021-01-14 مثبطات ببتيدية لمستقبلة انترلوكين-23 واستخدامها في معالجة الأمراض الالتهابية

Country Status (21)

Country Link
US (2) US11845808B2 (ar)
EP (1) EP4090670A4 (ar)
JP (2) JP7441955B2 (ar)
KR (1) KR20220141807A (ar)
CN (5) CN118005737A (ar)
AR (1) AR121070A1 (ar)
AU (1) AU2021207653A1 (ar)
BR (1) BR112022013957A2 (ar)
CA (1) CA3167751A1 (ar)
CL (1) CL2022001893A1 (ar)
CO (1) CO2022009931A2 (ar)
CR (1) CR20220332A (ar)
DO (1) DOP2022000147A (ar)
EC (1) ECSP22063238A (ar)
IL (1) IL294680A (ar)
JO (1) JOP20220169A1 (ar)
MX (1) MX2022008741A (ar)
PE (1) PE20230370A1 (ar)
PH (1) PH12022551750A1 (ar)
TW (1) TW202140517A (ar)
WO (1) WO2021146441A1 (ar)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2968443T3 (pl) 2013-03-15 2022-02-07 Protagonist Therapeutics, Inc. Analogi hepcydyny i ich zastosowania
CN113621027A (zh) 2014-05-16 2021-11-09 领导医疗有限公司 α4β7整联蛋白硫醚肽拮抗剂
ES2977537T3 (es) 2014-07-17 2024-08-26 Protagonist Therapeutics Inc Inhibidores peptídicos orales del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias intestinales
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
JP7534382B2 (ja) * 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
KR20220141808A (ko) 2020-01-15 2022-10-20 얀센 바이오테크 인코포레이티드 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
IL316550A (en) 2020-11-20 2024-12-01 Janssen Pharmaceutica Nv Compositions of interleukin-23 receptor peptide inhibitors
EP4370146A2 (en) * 2021-07-14 2024-05-22 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor
WO2023004414A1 (en) * 2021-07-23 2023-01-26 Colorado Chromatography, Llc A method for preparing hexahydrocannabinol
CA3240982A1 (en) 2021-12-01 2023-06-08 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN118829647A (zh) 2022-02-01 2024-10-22 詹森药业有限公司 白介素-23受体的肽抑制剂及其药物组合物
WO2023177452A1 (en) * 2022-03-14 2023-09-21 Colorado Chromatography, Llc Hydrogenation of cannabigerol and cannabichromene
WO2024003313A1 (en) 2022-06-30 2024-01-04 Sanofi New peptides as selective il-23 receptor antagonists
US20240218014A1 (en) * 2022-11-21 2024-07-04 Janssen Pharmaceutica Nv Synthesis of a cyclic peptide
TW202440611A (zh) * 2022-11-30 2024-10-16 大陸商上海翰森生物醫藥科技有限公司 多肽抑制劑、其製備方法和應用
WO2024155553A1 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Lipidated peptide inhibitors of interleukin-23 receptor
US20240279281A1 (en) * 2023-01-16 2024-08-22 Janssen Pharmaceutica Nv Peptide Inhibitors of Interleukin-23 Receptor
WO2024155547A2 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Peptide inhibitors of interleukin-23 receptor
WO2024163643A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv Methods for preparing crystalline peptide inhibitors of interleukin-23 receptor
WO2024186613A1 (en) * 2023-03-03 2024-09-12 Janssen Pharmaceutica Nv Interleukin-23 receptor antagonist peptides for use in the treatment of psoriasis
WO2024227437A1 (zh) * 2023-05-04 2024-11-07 西藏海思科制药有限公司 白介素-23受体的肽抑制剂制备及其用途
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2025051912A1 (en) * 2023-09-08 2025-03-13 Sanofi New peptides as selective il-23 receptor inhibitors

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US4724229A (en) 1986-09-30 1988-02-09 Smithkline Beckman Corporation Arg-arg-arg-vasopressin antagonists
JPH02306947A (ja) 1989-05-01 1990-12-20 Monsanto Co キラルβ―アミノ酸の製造方法
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
EP0578728B1 (en) 1991-04-05 1998-07-01 Genentech, Inc. PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIIIa
US5569741A (en) 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
EP0644772B1 (en) 1992-11-12 2003-04-02 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Opioid peptides
AU673731B2 (en) 1993-06-03 1996-11-21 Banyu Pharmaceutical Co., Ltd. Novel endothelin antagonistic peptide
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US5990084A (en) 1996-04-19 1999-11-23 Novo Nordisk A/S Compounds with growth hormone releasing properties
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
US7122623B2 (en) 1996-07-12 2006-10-17 Adherex Technologies, Inc. Compounds and methods for modulating cell adhesion
CA2264243C (en) 1996-08-30 2004-10-05 Novo Nordisk A/S Glp-1 derivatives
US5942492A (en) 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US5993811A (en) 1997-02-03 1999-11-30 Biology Associates, Llc Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
EP0998309A1 (en) 1997-07-11 2000-05-10 Innerdyne Medical, Inc. Methods and systems for preparing and sealing radiation delivery structures
US6818617B1 (en) 1997-08-15 2004-11-16 Temple University- Of The Commonwealth System Of Higher Education EC-3, an inhibitor of α4β1 and α4β7 integrins
US6271252B1 (en) 1997-11-24 2001-08-07 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
US8038984B2 (en) 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
WO2000006243A2 (en) 1998-07-28 2000-02-10 Innerdyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
AUPP616598A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Auxiliary for amide bond formation
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
AUPP660698A0 (en) 1998-10-21 1998-11-12 University Of Queensland, The A method of protein engineering
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CN1344248A (zh) 1999-03-17 2002-04-10 诺沃挪第克公司 肽的酰化方法和新酰化剂
BR0010599A (pt) 1999-04-12 2002-02-13 Aventis Pharma Ltd Compostos de heteroarila bicìclicos substituìdos como antagonistas de integrina
WO2001068586A2 (en) 2000-03-14 2001-09-20 Novartis Ag α4β1 AND α4β7 INTEGRIN INHIBITORS
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
RU2292904C2 (ru) 2001-01-09 2007-02-10 Мерк Патент Гмбх Комбинированная терапия, использующая ингибиторы рецептора тирозинкиназы и ингибиторы ангиогенезиса
DE10107707A1 (de) 2001-02-19 2002-08-29 Wilex Biotechnology Gmbh Antagonisten für alpha¶4¶beta¶7¶-Integrin
AUPS039702A0 (en) 2002-02-08 2002-03-07 University Of Queensland, The Common protein surface shapes and uses therefor
US20030166138A1 (en) 2002-02-21 2003-09-04 Todd Kinsella Cyclic peptides and analogs useful to treat allergies
CA2484941A1 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
WO2004058307A1 (en) 2002-12-18 2004-07-15 Wyeth Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
US20070032417A1 (en) 2002-12-24 2007-02-08 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
CA2522680A1 (en) 2003-04-15 2004-10-28 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
EP2332968B1 (en) 2003-11-05 2016-05-04 Dana-Farber Cancer Institute, Inc. Alpha-helical peptides suitable for activating or inhibiting cell death
WO2005064345A2 (en) 2003-12-19 2005-07-14 Applera Corporation Methods and systems for protein and peptide evidence assembly
EA012872B1 (ru) 2004-01-09 2009-12-30 Пфайзер Инк. АНТИТЕЛА ПРОТИВ MAdCAM
US8536140B2 (en) 2004-03-12 2013-09-17 Mti Meta Tech Inc. Methods for treating inflammatory bowel disease
US20070197430A1 (en) 2004-06-24 2007-08-23 Jonathan Baell Conjugates And Therapeutic Uses Thereof
CA2581319A1 (en) 2004-09-23 2006-03-30 The University Of Melbourne Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection
WO2006062685A2 (en) 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
JP2008521840A (ja) 2004-11-30 2008-06-26 ガストロテック・ファルマ・アクティーゼルスカブ 成長ホルモン分泌促進物質レセプター１ａリガンド
US20100183617A1 (en) 2005-02-23 2010-07-22 University Of Virginia Patent Foundation Compositions and methods for regulating sas1r
CA2549477A1 (en) 2005-06-29 2006-12-29 The Regents Of The University Of California Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin
JP2009509535A (ja) 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
US8076306B2 (en) 2006-04-12 2011-12-13 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
GB0610395D0 (en) 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
EP2044118A2 (en) 2006-06-13 2009-04-08 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
US20080019913A1 (en) 2006-07-07 2008-01-24 University Of Arizona Office Of Technology Transfer Enkepahlin analogs with improved bioavailability
CA2657338C (en) 2006-07-21 2013-10-22 Cristalia Produtos Quimicos Farmaceuticos Ltda. Anti-inflammatory and antiallergic cyclic peptides
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
US7713937B2 (en) 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
US9193790B2 (en) 2006-12-07 2015-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
TW201307390A (zh) 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
PL2059534T3 (pl) 2007-02-23 2012-09-28 Merck Sharp & Dohme Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
ES2465223T3 (es) 2007-04-27 2014-06-05 Zymogenetics, Inc. Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso
WO2008144041A1 (en) 2007-05-21 2008-11-27 The Ohio State University Research Foundation Hepcidins as biomarkers for impending lupus nephritis flare
US20090131317A1 (en) 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
CN101990547A (zh) 2007-07-06 2011-03-23 瓦勒瑞萨欣Hsj有限合伙公司 Il-23受体拮抗剂以及其应用
CN101358201A (zh) 2007-07-31 2009-02-04 钱忠明 重组人铁调素腺病毒、其制备方法及应用
CN101307085B (zh) 2007-08-01 2012-06-13 香港理工大学深圳研究院 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
GR1006896B (el) 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
WO2009039185A1 (en) 2007-09-17 2009-03-26 The Trustees Of Columbia University In The City Of New York Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation
US20100280098A1 (en) 2007-10-05 2010-11-04 Juliano Rudolph L Receptor targeted oligonucleotides
EP2352762A1 (en) 2008-11-03 2011-08-10 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
EP2373679B1 (en) 2008-12-05 2017-03-08 The Regents of The University of California Mini-hepcidin peptides and methods of using thereof
DE102009007381A1 (de) 2009-01-29 2010-08-05 Amp-Therapeutics Gmbh & Co. Kg Antibiotische Peptide
US8999935B2 (en) 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
JP5669728B2 (ja) 2009-04-08 2015-02-12 武田薬品工業株式会社 ニューロメジンｕ誘導体
TWI578992B (zh) 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類
US20110142889A1 (en) 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
EP3018138A1 (en) 2010-01-25 2016-05-11 Cornell University Aromatic-cationic peptides and uses of same
US9523073B2 (en) 2010-03-31 2016-12-20 Medical Diagnostic Laboratories, Llc Elisa for a naturally-occurring soluble truncated form of IL-23 receptor
JP2011231085A (ja) 2010-04-30 2011-11-17 Osaka Prefecture Univ 環状ペプチド
US20130236977A1 (en) 2010-05-24 2013-09-12 Children's Medical Center Corporation Compositions and methods for plasma peptide analysis
IT1406051B1 (it) 2010-08-05 2014-02-06 D M G Italia S R L Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
SI2603232T1 (sl) 2010-08-11 2020-03-31 Ironwood Pharmaceuticals, Inc. Stabilne formulacije linaklotida
EP2444101A1 (en) 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
EP2668199B1 (en) 2011-01-27 2017-09-06 Ramot at Tel Aviv University, Ltd. Glycogen synthase kinase-3 inhibitors
US9169292B2 (en) 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9605027B2 (en) 2011-06-14 2017-03-28 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US20150118315A1 (en) 2011-06-14 2015-04-30 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
EP2788370B1 (en) 2011-12-09 2020-02-05 The Regents of The University of California Modified mini-hepcidin peptides and methods of using thereof
US20150157692A1 (en) 2012-05-23 2015-06-11 The University Of Chicago Methods of treating obesity
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
JP2016508722A (ja) 2013-02-15 2016-03-24 エスアールエックス カーディオ，エル エル シー 血清低密度リポタンパク質（ｌｄｌ）レベルを調節するためのｐｃｓｋ９（プロタンパク質転換酵素サブチリシン／ケキシン９型）アロステリック結合リガンド
PL2968443T3 (pl) 2013-03-15 2022-02-07 Protagonist Therapeutics, Inc. Analogi hepcydyny i ich zastosowania
US20140294901A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide dimer antagonists
US20140294902A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
MX366341B (es) 2013-06-24 2019-07-05 Canbas Co Ltd Peptidos y peptidomimeticos en usos de combinacion y tratamientos para subpoblaciones de pacientes con cancer.
WO2014210056A1 (en) 2013-06-27 2014-12-31 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
AU2014331812B2 (en) 2013-10-09 2019-01-17 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
WO2015112700A1 (en) 2014-01-22 2015-07-30 Wisconsin Alumni Research Foundation Alpha/beta-peptide mimics of z-domain peptides
EP3129040A4 (en) 2014-04-07 2018-03-21 La Jolla Pharmaceutical Company Hepdicin mimetic peptides and uses thereof
CN113621027A (zh) 2014-05-16 2021-11-09 领导医疗有限公司 α4β7整联蛋白硫醚肽拮抗剂
WO2015183963A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including redox-active parabenzoquinones and uses thereof
SG11201610799WA (en) 2014-06-27 2017-01-27 Protagonist Therapeutics Inc Hepcidin and mini-hepcidin analogues and uses therof
WO2016004093A2 (en) 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
ES2977537T3 (es) * 2014-07-17 2024-08-26 Protagonist Therapeutics Inc Inhibidores peptídicos orales del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias intestinales
US9809623B2 (en) 2014-10-01 2017-11-07 Protagonist Therapeutics, Inc. α4β7 peptide monomer and dimer antagonists
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
CA2970962A1 (en) 2014-12-29 2016-07-07 The Regents Of The University Of California S-alkylated hepcidin peptides and methods of making and using thereof
US20160199437A1 (en) 2015-01-08 2016-07-14 D. Travis Wilson Therapeutic compositions including iron chelators and uses thereof
WO2016115168A1 (en) 2015-01-12 2016-07-21 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
US20160228491A1 (en) 2015-02-09 2016-08-11 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof
WO2016195663A1 (en) 2015-06-02 2016-12-08 Stealth Peptides International, Inc. Therapeutic compositions including bpm 31510, variants and analogues thereof, and uses thereof
WO2016200364A1 (en) 2015-06-08 2016-12-15 Stealth Peptides International, Inc. THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP3341011A4 (en) * 2015-07-15 2019-02-20 Protagonist Therapeutics Inc. PEPTIDINHIBITORS OF THE INTERLEUKIN 23 RECEPTOR AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISEASES
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2017165676A1 (en) 2016-03-23 2017-09-28 Protagonist Therapeutics, Inc. METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS
US20190264197A1 (en) 2016-07-27 2019-08-29 Protagonist Therapeutics, Inc. Disulfide-rich peptide libraries and methods of use thereof
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2018089693A2 (en) 2016-11-09 2018-05-17 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
JP7100034B2 (ja) 2016-12-06 2022-07-12 シュティヒティング・ヴォール・デ・テクニシェ・ヴェテンシャッペン 多環式ペプチド及びそれらの調製方法
EP3570864A4 (en) * 2017-01-18 2020-12-30 Protagonist Therapeutics, Inc. PEPTIDES OF INTERLEUKIN-23 RECEPTOR INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
WO2020014646A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3135024A1 (en) 2019-03-28 2020-10-01 Protagonist Therapeutics, Inc. Methods for synthesizing .beta.-homoamino acids
JP7534382B2 (ja) * 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
TW202116793A (zh) 2019-07-10 2021-05-01 美商領導醫療有限公司 介白素-23受體之肽抑制劑及其於治療發炎疾病的用途
MX2022002633A (es) 2019-09-03 2022-06-02 Protagonist Therapeutics Inc Mimeticos de hepcidina conjugada.
PH12022551651A1 (en) 2020-01-10 2023-11-20 Protagonist Therapeutics Inc METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH a4ß7 INTEGRIN ANTAGONISTS
US20230129095A1 (en) 2020-01-15 2023-04-27 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) * 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
KR20220141808A (ko) 2020-01-15 2022-10-20 얀센 바이오테크 인코포레이티드 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
CA3189432A1 (en) 2020-07-28 2022-02-03 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
IL316550A (en) 2020-11-20 2024-12-01 Janssen Pharmaceutica Nv Compositions of interleukin-23 receptor peptide inhibitors
US20240226225A1 (en) 2021-04-01 2024-07-11 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3213688A1 (en) 2021-04-01 2022-10-06 Ashok Bhandari Conjugated hepcidin mimetics
JP2024520861A (ja) 2021-06-14 2024-05-24 プロタゴニスト セラピューティクス， インコーポレイテッド 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体

Also Published As

Publication number Publication date
PE20230370A1 (es) 2023-03-06
AU2021207653A1 (en) 2022-08-04
US11845808B2 (en) 2023-12-19
DOP2022000147A (es) 2023-01-15
KR20220141807A (ko) 2022-10-20
BR112022013957A2 (pt) 2022-10-11
TW202140517A (zh) 2021-11-01
JP7441955B2 (ja) 2024-03-01
CN118027153A (zh) 2024-05-14
JP2023511552A (ja) 2023-03-20
ECSP22063238A (es) 2022-09-30
IL294680A (en) 2022-09-01
US20210261622A1 (en) 2021-08-26
EP4090670A1 (en) 2022-11-23
CA3167751A1 (en) 2021-07-22
CR20220332A (es) 2022-11-28
EP4090670A4 (en) 2024-11-20
PH12022551750A1 (en) 2023-11-13
CN118005736A (zh) 2024-05-10
WO2021146441A1 (en) 2021-07-22
US20240150405A1 (en) 2024-05-09
CN115298196A (zh) 2022-11-04
AR121070A1 (es) 2022-04-13
CN118063554A (zh) 2024-05-24
CL2022001893A1 (es) 2023-03-03
MX2022008741A (es) 2022-10-03
JP2023139158A (ja) 2023-10-03
CO2022009931A2 (es) 2022-10-21
CN118005737A (zh) 2024-05-10

Similar Documents

Publication Publication Date Title
PH12022551750A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2022000397A (es) Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
AR119389A1 (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2022008740A (es) Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
MX2024000760A (es) Inhibidores peptídicos lipídicos del receptor de interleucina-23.
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
MX2024000761A (es) Inhibidores peptidicos biciclicos del receptor de interleucina-23.
EP4378536A3 (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
MX2021005348A (es) Compuestos de piridazinonas y usos de los mismos.
PH12023552079A1 (en) Cdk2 inhibitors and methods of using the same
PH12022500003A1 (en) Il-2 conjugates and methods of use to treat autoimmune diseases
CR20240101A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-y (DIVISIONAL 2020-464)
PH12022550039A1 (en) Peptide conjugates of cytotoxins as therapeutics
MX2023009060A (es) Antagonistas de gpr84 y usos de estos.
MX2023009059A (es) Antagonistas de gpr84 y usos de estos.
MX2022010693A (es) Compuestos, composiciones y metodos para inhibidores de la proteina quinasa que interactua con el receptor i para el tratamiento de enfermedades.
PH12021552358A1 (en) Compounds and compositions as modulators of tlr signaling
PH12021550258A1 (en) Cdk8/19 inhibitors
PH12022550497A1 (en) Perk inhibiting compounds
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
EA202091524A1 (ru) Ингибиторы рецептора, активируемого протеазой 2
MX2021007967A (es) Inhibidores de síntesis de leucotrienos.
EA202092204A1 (ru) Композиции
LV15485A (lv) Selenofēnhromenonu hidroksāmskābes, to izgatavošana un izmantošana angioģenēzes inhibīcijā